RT Journal Article
SR Electronic
T1 Consensus on COVID-19 vaccination in pediatric oncohematological patients, on behalf of infectious working group of Italian Association of Pediatric Hematology Oncology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.06.22268792
DO 10.1101/2022.01.06.22268792
A1 Simone Cesaro
A1 Paola Muggeo
A1 Daniele Zama
A1 Monica Cellini
A1 Katia Perruccio
A1 Antonella Colombini
A1 Francesca Carraro
A1 Mariagrazia Petris
A1 Valeria Petroni
A1 Maurizio Mascarin
A1 Francesco Baccelli
A1 Elena Soncini
A1 Rosamaria Mura
A1 Milena Laspina
A1 Nunzia Decembrino
A1 Roberta Burnelli
A1 Stefano Frenos
A1 Elio Castagnola
A1 Maura Faraci
A1 Cristina Meazza
A1 Federica Barzaghi
A1 Maria Rosaria D’Amico
A1 Maria Capasso
A1 Elisabetta Calore
A1 Ottavio Ziino
A1 Angelica Barone
A1 Francesca Compagno
A1 Laura Luti
A1 Federica Galaverna
A1 Raffaella De Santis
A1 Letizia Brescia
A1 Linda Meneghello
A1 Angelamaria Petrone
A1 Nagua Giurici
A1 Fabian Schumacher
A1 Federico Mercolini
YR 2022
UL http://medrxiv.org/content/early/2022/01/08/2022.01.06.22268792.abstract
AB Vaccines represent the best tool to prevent the severity course and fatal consequences of pandemic by new Coronavirus 2019 infection (SARS-CoV-2). Considering the limited data on vaccination of pediatric oncohematological patients, we develop a Consensus document to support the Italian pediatric hematological oncological (AIEOP) centers in a scientifically correct communication with families and patients and to promote vaccination. The topics of the Consensus were: SARS-CoV-2 infection and disease (COVID-19) in the pediatric subjects; COVID-19 vaccines (type, schedule); which and when to vaccinate; contraindications and risk of serious adverse events; rare adverse events; third dose and vaccination after COVID-19; and other general prevention measures. Using the Delphi methodology for Consensus, 21 statements and their corresponding rationale were elaborated and discussed with the representatives of 31 centers, followed by voting. AIEOP Centers showed an overall agreement on all the statements that were therefore approved.This consensus document highlights that children and adolescents affected by hematological and oncological diseases are a fragile category. Vaccination plays an important role to prevent COVID-19, to permit the regular administration of chemotherapy or other treatments, to perform control visits and hospital admissions, and to prevent treatment delays.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscrip